Stock TARSUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Tarsus Pharmaceuticals, Inc. Nasdaq

Equities

US87650L1035

End-of-day quote Nasdaq
Other stock markets
 		5-day change 1st Jan Change
- USD -.--% Intraday chart for Tarsus Pharmaceuticals, Inc. -.--% -.--%
10/06 Transcript : Tarsus Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 02:00 PM
31/05 Certain Restricted Stock Units of Tarsus Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 31-MAY-2024. CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • Based on current prices, the company has particularly high valuation levels.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
TARSUS PHARMACEUTICALS, INC. Stock Tarsus Pharmaceuticals, Inc.
-.--% 1.07B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.55% 823B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+42.31% 641B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.83% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.15% 324B
B-
ABBVIE INC. Stock AbbVie Inc.
+7.09% 301B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.02% 241B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+1.64% 223B
A+
NOVARTIS AG Stock Novartis AG
+13.66% 218B
B-
AMGEN INC. Stock Amgen Inc.
+7.87% 167B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. TARS Stock
  4. Stock
  5. Ratings Tarsus Pharmaceuticals, Inc.